GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs) - APPROACH TO DIAGNOSIS AND MANAGEMENT

Overview

Journal Ann Ib Postgrad Med

Specialty General Medicine

Date 2014 Aug 28

PMID 25161467

Citations 3

Authors

A O Oladejo

Affiliations

Soon will be listed here.

Citing Articles

Budek M, Nuszkiewicz J, Piorkowska A, Czuczejko J, Szewczyk-Golec K Biomedicines. 2022; 10(10).

PMID: 36289922 PMC: 9599081. DOI: 10.3390/biomedicines10102660.

Estimation of Health-Related Utilities for Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities.

Soare I, Leeuwenkamp O, Longworth L Pharmacoecon Open. 2021; 5(4):715-725.

PMID: 34260017 PMC: 8611167. DOI: 10.1007/s41669-021-00280-9.

Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method.

Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O J Med Imaging (Bellingham). 2019; 7(1):012704.

PMID: 31824983 PMC: 6901275. DOI: 10.1117/1.JMI.7.1.012704.

References

Ricke J, Klose K . Imaging procedures in neuroendocrine tumours. Digestion. 2000; 62 Suppl 1:39-44. DOI: 10.1159/000051854. View

Kulke M, Mayer R . Carcinoid tumors. N Engl J Med. 1999; 340(11):858-68. DOI: 10.1056/NEJM199903183401107. View

Thorson A, BIORCK G, BJORKMAN G, Waldenstrom J . Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and.... Am Heart J. 1954; 47(5):795-817. DOI: 10.1016/0002-8703(54)90152-0. View

Janson E, Oberg K . Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993; 32(2):225-9. DOI: 10.3109/02841869309083916. View

Yao J, Phan A, Chang D, Wolff R, Hess K, Gupta S . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26(26):4311-8. PMC: 2653122. DOI: 10.1200/JCO.2008.16.7858. View

Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J . Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14(2):221-32. DOI: 10.1677/ERC-06-0074. View

Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, Oei H . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8):716-31. DOI: 10.1007/BF00181765. View

Fjallskog M, Granberg D, Welin S, Eriksson C, Oberg K, Janson E . Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001; 92(5):1101-7. DOI: 10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v. View

Rufini V, Calcagni M, Baum R . Imaging of neuroendocrine tumors. Semin Nucl Med. 2006; 36(3):228-47. DOI: 10.1053/j.semnuclmed.2006.03.007. View

10.

Kwekkeboom D, Bakker W, Kam B, Teunissen J, Kooij P, de Herder W . Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003; 30(3):417-22. PMC: 1998890. DOI: 10.1007/s00259-002-1050-8. View

11.

Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio A . Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer. 1993; 72(10):3099-105. DOI: 10.1002/1097-0142(19931115)72:10<3099::aid-cncr2820721035>3.0.co;2-4. View

12.

Yao J, Phan A, Hoff P, Chen H, Charnsangavej C, Yeung S . Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26(8):1316-23. DOI: 10.1200/JCO.2007.13.6374. View

13.

Ben-Shlomo A, Melmed S . Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs. 2007; 10(12):885-95. View

14.

Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G . Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000; 23(4):412-5. DOI: 10.1097/00000421-200008000-00020. View

15.

Kvols L, Brown M, OConnor M, Hung J, Hayostek R, Reubi J . Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology. 1993; 187(1):129-33. DOI: 10.1148/radiology.187.1.8383865. View

16.

Eriksson B, Oberg K, Stridsberg M . Tumor markers in neuroendocrine tumors. Digestion. 2000; 62 Suppl 1:33-8. DOI: 10.1159/000051853. View

17.

Kloppel G, Perren A, Heitz P . The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13-27. DOI: 10.1196/annals.1294.002. View

18.

Lamberts S, Bakker W, Reubi J, Krenning E . Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990; 323(18):1246-9. DOI: 10.1056/NEJM199011013231805. View

19.

Kwekkeboom D, Mueller-Brand J, Paganelli G, Anthony L, Pauwels S, Kvols L . Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1:62S-6S. View

20.

Cheslyn-Curtis S, Sitaram V, Williamson R . Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg. 1993; 80(5):625-7. DOI: 10.1002/bjs.1800800528. View